EyePoint 경영진
경영진 기준 점검 3/4
EyePoint CEO는 Jay Duker, Jan2023 에 임명되었습니다 의 임기는 3.33 년입니다. 총 연간 보상은 $5.57M, 12.5% 급여 및 87.5% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $2.31M 가치에 해당하는 회사 주식의 0.21% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.8 년과 4.8 년입니다.
핵심 정보
Jay Duker
최고경영자
US$5.6m
총 보수
| CEO 급여 비율 | 12.50% |
| CEO 재임 기간 | 3.3yrs |
| CEO 지분 보유율 | 0.2% |
| 경영진 평균 재임 기간 | 3.8yrs |
| 이사회 평균 재임 기간 | 4.8yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 20
EYPT: Phase 3 Eye Disease Program Will Drive Future Upside Potential
Narrative Update on EyePoint Analysts have adjusted the average price target on EyePoint to $37.00 from $37.17. This change reflects recent upward target revisions into the $29 to $35 range as they consider updated Q4 results, progress on Duravyu programs, and the inclusion of the Phase 3 diabetic macular edema program in their valuation work.Seeking Alpha • May 14
EyePoint: DURAVYU's Durability Could Drive Significant Upside
Summary EyePoint is rated a clear BUY, with central-case DCF modeling indicating roughly 2x upside from current levels. DURAVYU, EYPT's lead candidate for wet AMD and DME, has demonstrated a compelling durability profile in Phase 2 and could benefit from a large, high-turnover wet AMD market if confirmed. Probability-adjusted DCF values DURAVYU at ~$2.9B pre-dilution, with a final equity value of ~$2.3B and ~$27/share after an estimated 20% dilution. Key risks include a ~39% chance of Phase 3 failure, regulatory complexities as a drug-device, and commercial adoption uncertainty amid evolving competition. Read the full article on Seeking Alpha내러티브 업데이트 • May 04
EYPT: Phase 3 DME Pivotal Program Will Drive Future Upside Potential
Analysts have raised EyePoint's average price target by $6, from $29 to $35, citing updated post-Q4 estimates, the inclusion of the Phase 3 diabetic macular edema program in valuation, and refreshed views on the Duravyu programs. Analyst Commentary Recent Street research reflects a more constructive stance on EyePoint, with several firms updating their valuation frameworks after the Q4 report and program updates.내러티브 업데이트 • Apr 19
EYPT: Phase 3 Diabetic Macular Edema Program Will Underpin Future Upside Potential
Narrative update on EyePoint The fair value estimate for EyePoint edges down slightly to $37.17 from $37.42, even as analysts lift published price targets to a range of $29 to $35. They cite updated models after Q4 results, inclusion of the Phase 3 diabetic macular edema program, and refreshed assumptions around the Duravyu programs.내러티브 업데이트 • Apr 04
EYPT: Phase 3 Diabetic Macular Edema Program Will Drive Further Upside
Analysts have lifted EyePoint's implied upside in their models, with recent Street price targets moving from a prior range of about $23 to $31 up to $29 to $35, citing updated estimates after Q4 results, the inclusion of the Phase 3 diabetic macular edema program in valuations, and progress across Duravyu programs. Analyst Commentary Bullish Takeaways Bullish analysts are marking up their price targets into a US$29 to US$35 range, which indicates higher expectations around execution and value creation after the recent Q4 update.내러티브 업데이트 • Mar 20
EYPT: Phase 3 Diabetic Macular Edema Trials Will Support Further Upside
Narrative Update on EyePoint Analysts have lifted the average price target on EyePoint by about $0.33 to $37.42 as recent research updates incorporate Phase 3 diabetic macular edema expectations and refreshed estimates following the Q4 report. Analyst Commentary Recent research updates on EyePoint focus on refreshed valuation work after the Q4 report and the inclusion of specific pipeline programs in analysts’ models.내러티브 업데이트 • Mar 06
EYPT: Phase 3 Diabetic Macular Edema Program Will Drive Future Upside
Analysts have raised their average price target for EyePoint to approximately $37 per share, up from about $36. They attribute this change to updated assumptions following the Q4 results, including the integration of the Phase 3 diabetic macular edema program and revised expectations for the Duravyu franchise.내러티브 업데이트 • Feb 19
EYPT: Rebrand And Refined Profit Outlook Will Support Future Upside
Analysts now set a refreshed price target for EyePoint at $36.08, with the update linked to modest adjustments in the discount rate, profit margin expectations, and future P/E assumptions. What's in the News On December 8, 2025, EyePoint Pharmaceuticals, Inc.분석 기사 • Feb 04
EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
The EyePoint, Inc. ( NASDAQ:EYPT ) share price has softened a substantial 27% over the previous 30 days, handing back...내러티브 업데이트 • Jan 19
EYPT: Phase 3 Safety Progress And Rebrand Will Support Future Upside
Analysts have raised their price target on EyePoint to reflect updated assumptions on profit margin and future P/E. The new target is now approximately $36.08 per share.내러티브 업데이트 • Jan 05
EYPT: Recent Capital Raise And Lock Ups Will Support Future Upside
Analysts have slightly raised their price target on EyePoint to US$36.08, with the modest adjustment tied to unchanged fair value assumptions and very small tweaks to inputs like discount rate, revenue growth, profit margin and future P/E expectations. What's in the News EyePoint Pharmaceuticals, Inc.내러티브 업데이트 • Dec 20
EYPT: Phase 3 Ocular Trial Progress Will Drive Future Upside Potential
Analysts have raised their price target on EyePoint from approximately $34.42 to $36.08 per share. This reflects increased confidence in the company’s significantly higher projected revenue growth, despite a modestly higher discount rate and slightly lower forecast profit margins and future valuation multiples.분석 기사 • Dec 12
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
EyePoint, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a great month, posting...분석 기사 • Sep 06
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Looks Just Right With A 32% Price Jump
Despite an already strong run, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have been powering on, with a gain...내러티브 업데이트 • Aug 15
Phase III Trials In Wet AMD Will Expand Market Reach
EyePoint Pharmaceuticals’ consensus price target remained unchanged at $34.42, as strong Phase 2 data and operational improvements offset in-line clinical progress in the development of Duravyu. Analyst Commentary Completion of enrollment in the second Phase 3 LUCIA study for Duravyu.분석 기사 • Jun 16
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
The EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) share price has done very well over the last month, posting an...분석 기사 • May 03
Is EyePoint Pharmaceuticals (NASDAQ:EYPT) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
새로운 내러티브 • Mar 27
DURAVYU Phase III Trials Will Accelerate Market Entry
Expedited Phase III trial progress and robust patent protection could maximize long-term revenue and margin potential for DURAVYU.분석 기사 • Mar 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year
Shareholders of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) will be pleased this week, given that the stock price is...분석 기사 • Feb 26
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Jan 30
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
Summary EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoing Phase 3 studies suggest significant upside potential, though past mixed results and heavy competition raise risks. Recent fundraising and a new manufacturing facility indicate strong commitment, but the company's financial health and market skepticism remain concerns. I maintain a "risky buy" rating, believing in the potential for substantial gains if pivotal studies succeed, despite the inherent risks and competition. Read the full article on Seeking Alpha분석 기사 • Dec 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a horrible month, losing 29% after a relatively good...Seeking Alpha • Nov 14
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Summary EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety, and efficacy, and reduced treatment burden, positioning it as a potential long-term solution for retinal diseases. Despite a failed NPDR trial, positive DME data suggest potential for targeting more severe diabetic retinopathy, enhancing the investment thesis. EyePoint's financials are robust with a cash runway into 2027, but risks include phase 3 trial outcomes and competition from entrenched anti-VEGF therapies. Read the full article on Seeking Alpha분석 기사 • Oct 29
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a really impressive month, gaining 52% after a shaky...분석 기사 • Sep 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Key Insights The projected fair value for EyePoint Pharmaceuticals is US$12.22 based on 2 Stage Free Cash Flow to...Seeking Alpha • Aug 29
EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Summary EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boosted EyePoint's stock but concerns remain about efficacy, financial strength, competition, and patient/physician adoption. A recent NPDR study failure caused a significant stock drop, but upcoming Phase 3 Wet AMD and Phase 2 DME data could provide new catalysts for gains. Despite risks, I upgrade EyePoint to "Buy" due to potential price volatility and multiple upcoming data catalysts that could drive significant gains. Read the full article on Seeking Alpha분석 기사 • Aug 15
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) - they aren't optimistic...분석 기사 • Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
As you might know, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) last week released its latest second-quarter, and...분석 기사 • Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Unfortunately for some shareholders, the EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) share price has dived 27% in...Seeking Alpha • May 06
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
Summary EyePoint Pharmaceuticals, Inc. stock surged following positive Phase 2 trial outcomes in wet AMD, showing non-inferiority to Eylea. Despite success in wet AMD, 1901 showed disappointing results in an NPDR trial, failing its primary endpoint. Financially, EyePoint is sound with a healthy current ratio and sufficient cash runway, yet facing significant future costs. Investment recommendation: Downgrade EYPT to "Sell" due to high risks and competitive pressures, despite some positive trial results. Read the full article on Seeking Alpha분석 기사 • Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a horrible month, losing 26% after a relatively good...Seeking Alpha • Feb 20
EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Summary EyePoint Pharmaceuticals' EYP-1901 drug for wet AMD showed positive results in Phase 2 clinical trials, potentially offering a lower-cost and more effective treatment option. The company's proprietary Durasert E technology delivers drugs directly to the eye, maximizing efficacy and minimizing side effects. The company's financials show a decent cash runway, but with high cash burn and premium valuation, financial stability is a concern. Despite promising technology and pipeline, EyePoint Pharmaceuticals' high valuation suggests its stock's potential upside is already reflected in the price. Therefore, I think EYPT is a "hold" for now. Read the full article on Seeking Alpha분석 기사 • Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Despite an already strong run, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have been powering on, with a gain...분석 기사 • Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, EyePoint Pharmaceuticals fair value estimate is US$36.54...분석 기사 • Dec 18
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a...분석 기사 • Dec 13
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Today is shaping up negative for EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders, with the analysts...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$272m |
| Dec 31 2025 | US$6m | US$696k | -US$232m |
| Sep 30 2025 | n/a | n/a | -US$206m |
| Jun 30 2025 | n/a | n/a | -US$175m |
| Mar 31 2025 | n/a | n/a | -US$147m |
| Dec 31 2024 | US$6m | US$670k | -US$131m |
| Sep 30 2024 | n/a | n/a | -US$104m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
보상 대 시장: Jay의 총 보수(USD5.57M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.70M)보다 높습니다.
보상과 수익: Jay의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Jay Duker (66 yo)
3.3yrs
재임 기간
US$5,568,352
보수
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. Dr. Duker is t...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 3.3yrs | US$5.57m | 0.21% $ 2.3m | |
| Executive VP & CFO | 6.5yrs | US$2.17m | 0.14% $ 1.5m | |
| Chief Medical Officer | 2.2yrs | US$2.16m | 데이터 없음 | |
| Chief Scientific Officer | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer & Company Secretary | 7.5yrs | 데이터 없음 | 데이터 없음 | |
| Chief People Officer & Senior VP of IT | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President | 6.9yrs | US$1.46m | 데이터 없음 | |
| Chief Regulatory Officer | 4.2yrs | 데이터 없음 | 데이터 없음 | |
| Chief Manufacturing Officer | 1.4yrs | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | 데이터 없음 |
3.8yrs
평균 재임 기간
58.5yo
평균 나이
경험이 풍부한 관리: EYPT의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.8 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 2.8yrs | US$5.57m | 0.21% $ 2.3m | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | 데이터 없음 | |
| Independent Non-Executive Chairman | 7.9yrs | US$368.27k | 0.016% $ 170.0k | |
| Independent Director | 6.8yrs | US$339.69k | 0.012% $ 128.9k | |
| Vice Chair | 9.7yrs | US$339.69k | 0.50% $ 5.4m | |
| Co- Chairman of Scientific Advisory Board | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Director | 7.6yrs | US$310.94k | 0.026% $ 276.7k | |
| Independent Director | 3.8yrs | US$332.19k | 0.046% $ 497.8k | |
| Co-Chair of Scientific Advisory Board | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.8yrs | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
67yo
평균 나이
경험이 풍부한 이사회: EYPT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 04:53 |
| 종가 | 2026/05/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
EyePoint, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Colleen Kusy | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Timothy Chiang | Capital One Securities, Inc. |